.

Make Better Decisions

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Daiichi Sankyo
Harvard Business School
Fish and Richardson
Johnson and Johnson
Julphar
Boehringer Ingelheim
QuintilesIMS
Baxter
McKesson
AstraZeneca

Generated: September 23, 2017

DrugPatentWatch Database Preview

Methylphenidate - Generic Drug Details

« Back to Dashboard

What are the generic sources for methylphenidate and what is the scope of methylphenidate freedom to operate?

Methylphenidate
is the generic ingredient in fourteen branded drugs marketed by Noven Pharms Inc, Neos Theraps Inc, Nextwave Pharms, Mallinckrodt, Tris Pharma Inc, Ucb Inc, Novel Labs Inc, Able, Impax Labs Inc, Teva Pharms, Mallinckrodt Inc, Watson Labs, Sun Pharm Inds Inc, Ascent Pharms Inc, Actavis Labs Fl Inc, Janssen Pharms, Actavis Elizabeth, Mylan Pharms Inc, Osmotica, Novartis, Rhodes Pharms, Barr Labs Inc, Abhai Inc, Cnty Line Pharms, Nostrum Labs Inc, Tedor Pharma Inc, Mayne Pharma, Pfizer Inc, Abhai Llc, Vintage Pharms, and Kremers Urban Pharms, and is included in fifty-three NDAs. There are thirty-five patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Methylphenidate has forty-five patent family members in twenty-eight countries.

There are thirty-one drug master file entries for methylphenidate. Two suppliers are listed for this compound. There are two tentative approvals for this compound.

Summary for Generic Name: methylphenidate

Tradenames:14
Patents:35
Applicants:31
NDAs:53
Drug Master File Entries: see list31
Suppliers / Packagers: see list2
Bulk Api Vendors: see list16
Clinical Trials: see list340
Patent Applications: see list5,456
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:methylphenidate at DailyMed

Pharmacology for Ingredient: methylphenidate

Tentative approvals for METHYLPHENIDATE

Applicant Application No. Strength Dosage Form
► Subscribe► Subscribe10MGCAPSULE, EXTENDED RELEASE; ORAL
► Subscribe► Subscribe60MGCAPSULE, EXTENDED RELEASE;ORAL
► Subscribe► Subscribe50MGCAPSULE, EXTENDED RELEASE;ORAL
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Neos Theraps Inc
COTEMPLA XR-ODT
methylphenidate
TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL205489-001Jun 19, 2017RXYesNo► Subscribe► SubscribeY ► Subscribe
Vintage Pharms
METHYLPHENIDATE HYDROCHLORIDE
methylphenidate hydrochloride
TABLET;ORAL202892-003Sep 23, 2014ABRXNoNo► Subscribe► Subscribe► Subscribe
Rhodes Pharms
APTENSIO XR
methylphenidate hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL205831-002Apr 17, 2015RXYesNo► Subscribe► SubscribeY ► Subscribe
Abhai Inc
METHYLPHENIDATE HYDROCHLORIDE
methylphenidate hydrochloride
TABLET;ORAL206932-001May 11, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe
Rhodes Pharms
APTENSIO XR
methylphenidate hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL205831-004Apr 17, 2015RXYesNo► Subscribe► SubscribeY ► Subscribe
Ucb Inc
METADATE CD
methylphenidate hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL021259-002Jun 19, 2003AB2RXYesNo► Subscribe► SubscribeY ► Subscribe
Janssen Pharms
CONCERTA
methylphenidate hydrochloride
TABLET, EXTENDED RELEASE;ORAL021121-001Aug 1, 2000ABRXYesNo► Subscribe► SubscribeY► Subscribe
Impax Labs Inc
METHYLPHENIDATE HYDROCHLORIDE
methylphenidate hydrochloride
TABLET, EXTENDED RELEASE;ORAL208607-003Jul 14, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe
Ucb Inc
METHYLPHENIDATE HYDROCHLORIDE
methylphenidate hydrochloride
TABLET;ORAL085799-001Approved Prior to Jan 1, 1982ABRXNoNo► Subscribe► Subscribe► Subscribe
Novartis
RITALIN LA
methylphenidate hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL021284-004Apr 10, 2004AB1RXYesNo► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: methylphenidate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Noven Pharms Inc
DAYTRANA
methylphenidate
FILM, EXTENDED RELEASE;TRANSDERMAL021514-003Apr 6, 2006► Subscribe► Subscribe
Noven Pharms Inc
DAYTRANA
methylphenidate
FILM, EXTENDED RELEASE;TRANSDERMAL021514-004Apr 6, 2006► Subscribe► Subscribe
Noven Pharms Inc
DAYTRANA
methylphenidate
FILM, EXTENDED RELEASE;TRANSDERMAL021514-001Apr 6, 2006► Subscribe► Subscribe
Noven Pharms Inc
DAYTRANA
methylphenidate
FILM, EXTENDED RELEASE;TRANSDERMAL021514-002Apr 6, 2006► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: methylphenidate

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,017,731Composition comprising a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles to form drug resin particles► Subscribe
8,916,191Device for transdermal administration of drugs including acrylic polymers► Subscribe
9,265,737Pharmaceutical composition comprising amphetamines complexed with ion-exchange resin particles► Subscribe
8,709,491Composition comprising a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles to form drug resin particles► Subscribe
9,333,263Device for transdermal administration of drugs including acrylic based polymers► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: methylphenidate

Country Document Number Estimated Expiration
European Patent Office2314288► Subscribe
European Patent Office1459741► Subscribe
Austria260652► Subscribe
Japan2002510600► Subscribe
New Zealand505689► Subscribe
Hong Kong1156872► Subscribe
Denmark1037615► Subscribe
Poland341596► Subscribe
Norway329974► Subscribe
Brazil9814282► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Johnson and Johnson
Julphar
Boehringer Ingelheim
AstraZeneca
Colorcon
Federal Trade Commission
Teva
Covington
McKesson
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot